Here are four much-watch videos on the need to assess all maternal patients for the risk of VTE and to provide the recommended prophylaxis treatment, depending on whether the mother is antepartum or postpartum.
Hospital-associated thrombosis is a global problem. In a major study sponsored by the World Health Organization (WHO), it accounted for more deaths and disability than hospital-acquired pneumonia, catheter-related bloodstream infections, or adverse drug events in low and middle-income countries.
Venous thromboembolism (VTE) is a condition in which a blood clot forms most often in the deep veins of the leg, groin or arm (known as deep vein thrombosis, DVT) and travels in the circulation, lodging in the lungs (known as pulmonary embolism, PE). Together, DVT and PE are known as VTE - a dangerous, potentially deadly medical condition.
In summary, low-quality evidence indicates that thrombolytics may reduce mortality and recurrent PE in patients with acute PE. However, thrombolytics significantly increase the risk of major and minor hemorrhagic events. Therefore, we assign a color rating of Yellow (unknown benefit) to thrombolytic therapy for undifferentiated PE. Further high-quality studies are needed to determine whether specific patient groups, particularly those with submassive or massive PE, may benefit from thrombolytic therapy or suffer harm from these agents.
Although relatively common and associated with reduced survival, substantial health-care costs, and frequent reoccurrence, many VTE prevention efforts fail due to lack of standardized guidance integrated at the point of care or due to flawed risk assessment models that either offer no guidance or are so complicated that providers bypass them.
Birth control methods that contain estrogen increase the risks of blood clots by altering the delicate balance of clotting factors produced in the liver. In spite of this, however, most women taking estrogen don’t get clots. So, other factors must also be at play for a clot to form. Here are those other factors that we know and understand...
Researchers report that long-distance travel can raise your risk of a life-threatening venous thromboembolism (VTE) as much as threefold. In addition, risk increases relative to the duration of your trip--by a whopping 26 percent for every two hours of air travel and by 18 percent for every two hours of any other kind of travel--even if you are otherwise healthy.
Venous thromboembolism (VTE), a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death. Despite effective new options for prevention and treatment, VTE remains a threat underappreciated by the general public, causing up to 100,000 deaths annually in the United States alone.
You’re working up your new internal medicine patients on rotation. You’re investigating that meropenem, that sevelamer, and that pamidronate. Your patients have meningitis and pneumonia. SO much to learn. SO complex.
And then, BAM. Your preceptor asks you about VTE prophylaxis. And you’re like, ummm, but I know this cool new thing about meropenem? But they don’t let you off the hook. They want to know about that blood thinner.
Almost half of clots strike patients when they are in the hospital or soon after discharge, ranking them among the most common causes of preventable deaths. Guidelines for preventing clots are in place, yet studies show that 40% to 60% of patients who would benefit don't receive appropriate treatments. They aren’t given anticlotting drugs because hospitals don’t reliably administer them and patients sometimes refuse them.
Though VTE most often happens to adults over 40, any patient on bed rest after illness or surgery is vulnerable, even after being discharged from hospital. It is the leading cause of maternal death associated with childbirth, which puts pressure on deep veins.
Women who fall pregnant through in vitro fertilisation are at a higher risk of blood clots and artery blockages than women who get pregnant spontaneously, a new study has found.
Compression devices tether patients to bed, and they are noisy and often uncomfortable. Although pneumatic compression likely is useful if a patient has a contraindication to pharmacologic prophylaxis, routine dual VTE prophylaxis use warrants reconsideration. I would consider adding compression devices for particularly high-risk patients, but, for most patients, heparin or low-molecular-weight heparin alone should suffice.
I nearly died when I was 18 years old because I was taking birth control pills and did not realize I had a blood clot. Neither did my doctor. For five weeks. After traveling up my legs with no symptoms and lodging just below my heart, the pulmonary embolism grew to block 70% of my vena cava. The cause was taking birth control pills. While oral contraception overall has an impressive safety profile, knowing the risk factors for blood clots and the symptoms of one are important for those who take them.
A doubling of life-expectancy and a quadrupling of the
world population during the 20th century have been associated with a transition from infectious to non-communicable diseases as the major causes of death and disability
worldwide. Cardiovascular disease is a leading
contributor to the burden caused by non-communicable
diseases. Thrombosis is the most common underlying
pathology of the three major cardiovascular disorders:
ischemic heart disease (acute coronary syndrome), stroke,
and venous thromboembolism (VTE).
The advantages of these pathways are that they offer clear, evidence-based guidance for the identification, diagnosis and treatment of patients who can safely be treated in the outpatient setting, and provide a detailed, stepwise process that can be easily adapted to suit the needs of other institutions.
Thrombosis can affect anyone, regardless of their age, gender or ethnicity. Even those who are young and active can be susceptible to blood clots. However, there are steps that you can take to protect your health:
Venous thromboembolism (VTE) may contribute to up to 12% of deaths in ICU and is the No.1 preventable cause of hospital death.
This Is Serious is a national campaign to drive awareness and action around the prevention of Deep Vein Thrombosis (DVT), or blood clots, in women.
The campaign was developed by Dr. Thomas Ortel of the Duke Hemostasis and Thrombosis Center in partnership with the Centers for Disease Control and Prevention (CDC). This campaign is a multi-media program aimed at educating women about DVT and PE and motivating them to take action if they believe they may be at risk.
A Venous & Arterial Thrombosis Resource For Physicians.
Celebrated year round, World Thrombosis Day (WTD) is recognized on 13 October each year. WTD focuses attention on the often overlooked and misunderstood disease of thrombosis. With thousands of educational events in countries around the world, WTD and its partners place a global spotlight on thrombosis as an urgent and growing health problem.
Bringing together communities around the world to #KnowThrombosis, the quiet, underlying disorder that is the common mechanism of the world’s three top cardiovascular killers – heart attack, stroke and venous thromboembolism (VTE) – the International Society on Thrombosis and Haemostasis (ISTH) launched WTD in 2014.
The Clinical Leaders of Thrombosis (CLOT) is a special interest group which unites multi-disciplinary healthcare professionals working in the field of Haemostasis and Thrombosis.CLOT supports its members to deliver a high quality of care to patients.This is achieved by the sharing of knowledge and experience which helps to shape future services and advance the boundaries of healthcare delivery.
ClotCare strives to help others improve lives by providing both patients and healthcare providers with the most up-to-date information and expert insight on optimal use of antithrombotic and anticoagulant therapy.
Clot Connect provides patients and healthcare professionals connection to clinically relevant education resources on deep vein thrombosis, pulmonary embolism, thrombophilia and anticoagulation.
The International Society on Thrombosis and Haemostasis (ISTH) advances the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and hemostasis.
The National Blood Clot Alliance (NBCA) foresees a future in which the number of people suffering and dying from blood clots in the United States is reduced significantly. (NBCA) foresees a future in which the number of people suffering and dying from blood clots in the United States is reduced significantly.
NATF is dedicated to improving the lives of those affected by blood clots and related diseases. Through our comprehensive resources and innovative programming, we strive to educate patients and healthcare providers about thrombosis and its complications.
Thrombotic vascular disease, which encompasses myocardial ischemia, stroke, peripheral arterial disease, and venous thromboembolism, represents the single greatest risk to the health of Canadians.
Internationally renowned for pioneering, multi-disciplinary research, the Thrombosis Research Institutes are dedicated to the study of thrombosis and related disorders.
The Thrombosis Charity wishes to increase awareness of thrombosis among the public and health professionals and to raise research funds to improve patient care through improved prevention and treatment of venous thromboembolic disease.
An Internet Resource on Venous Thromboembolism
Every issue of Clinical and Applied Thrombosis/Hemostasis (CATH) addresses the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and vascular disorders.
The mission of the Journal of Thrombosis and Haemostasis is to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community.
Thrombosis Journal is aimed at the field of thrombotic diseases. This online journal publishes original articles on aspects of clinical and basic research, new methodology, case reports and review in the areas of thrombosis (platelets, coagulation fibrinolysis and vessel wall, risk factors for thrombosis and atherosclerosis) and related pathologies such as dyslipemia, hypertension, diabetes, immunology and obesity
As the world's leading publisher of science and health information, Elsevier serves more than 30 million scientists, students, and health and information professionals worldwide.
Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. It is important to know about VTE because it can happen to anybody at any age and cause serious illness, disability, and in some cases, death. The good news is that VTE can be prevented and treated if discovered early.